glp-1 and insulin Favorable Effects of Receptor Agonist against Pancreatic β-Cell Glucose Toxicity the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine GLP-1R and Diabetes

C.NappiF.AlbaneseL.et al (2017)

Aging Cell 18 , e12945 (2019)

This study demonstrated that the long-acting GLP-1R agonist, NLY01, has different health benefits in two different mouse models of MS

Split dosing (morning and afternoon) is less common but used by some

At 168 h, increases in TE might be attributed to the improvement of total antioxidant capacity compared to 0 h with subsequent amelioration of the OS status that may enhance the functionality of the cellular matrix of the testis including Sertoli, Leydig, and the spermatogenic cells (59)

This demonstrates how the incretin hormones are dependent on their receptor being present on islet beta-cells to mediate their insulinotropic effects